Open Access
Issue
Med Sci (Paris)
Volume 34, Number 10, Octobre 2018
Page(s) 824 - 832
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2018208
Published online 19 November 2018
  1. Maxim LD, Niebo R, Utell MJ. Screening tests: a review with examples. Inhal Toxicol 2014 ; 26 : 811–828. [CrossRef] [Google Scholar]
  2. Wilson JMG, , Jungner G. Principles and practice of screening for disease 1968 ; Geneva, World Health Organisation, 164 p [Google Scholar]
  3. Andermann A, Blancquaert I, Beauchamp S, et al. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008 ; 86 : 317–319. [CrossRef] [PubMed] [Google Scholar]
  4. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation. Casp J Intern Med 2013 ; 4 : 627–635. [Google Scholar]
  5. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007 ; 357 : 1579–1588. [CrossRef] [PubMed] [Google Scholar]
  6. Stieber P, Nagel D, Blankenburg I, et al. Diagnostic efficacy of CA 15–3 and CEA in the early detection of metastatic breast cancer: a retrospective analysis of kinetics on 743 breast cancer patients. Clin Chim Acta 2015 ; 448 : 228–231. [CrossRef] [Google Scholar]
  7. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991 ; 324 : 1156–1161. [CrossRef] [PubMed] [Google Scholar]
  8. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 ; 360 : 1310–1319. [CrossRef] [PubMed] [Google Scholar]
  9. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009 ; 360 : 1320–1328. [CrossRef] [PubMed] [Google Scholar]
  10. Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med 2017 ; 167 : 449–455. [CrossRef] [PubMed] [Google Scholar]
  11. Chen JS, Chen KT, Fan WC, et al. Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. Clin Chem Lab Med 2010 ; 48 : 719–725. [PubMed] [Google Scholar]
  12. Song LL, Li YM. Current noninvasive tests for colorectal cancer screening: an overview of colorectal cancer screening tests. World J Gastrointest Oncol 2016 ; 8 : 793–800. [CrossRef] [PubMed] [Google Scholar]
  13. Dhaliwal A, Vlachostergios PJ, Oikonomou KG, et al. Fecal DNA testing for colorectal cancer screening: molecular targets and perspectives. World J Gastrointest Oncol 2015 ; 7 : 178–183. [CrossRef] [PubMed] [Google Scholar]
  14. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004 ; 351 : 2704–2714. [CrossRef] [PubMed] [Google Scholar]
  15. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014 ; 370 : 1287–1297. [CrossRef] [PubMed] [Google Scholar]
  16. NCI dictionary of cancer terms Natl Cancer Inst nd. https://www.cancer.gov/publications/dictionaries/cancer-terms. [Google Scholar]
  17. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l’homme. CR Seances Soc Biol Fil 1948 ; 142 : 241–243. [Google Scholar]
  18. Stroun M, Anker P, Lyautey J, et al. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 1987 ; 23 : 707–712. [CrossRef] [PubMed] [Google Scholar]
  19. Thierry AR, El Messaoudi S, Gahan PB, et al. Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev 2016 ; 35 : 347–376. [CrossRef] [PubMed] [Google Scholar]
  20. Ilie M, Hofman V, Long E, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014; 2 : 107. [Google Scholar]
  21. Wan JCM, Massie C, , Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 2017 ; 17 : 223–238. [CrossRef] [Google Scholar]
  22. Mouliere F, El Messaoudi S, Pang D, et al. Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer. Mol Oncol 2014 ; 8 : 927–941. [CrossRef] [PubMed] [Google Scholar]
  23. Church TR, Wandell M, , Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2014 ; 63 : 317–325. [CrossRef] [PubMed] [Google Scholar]
  24. Lamb YN, Dhillon S. Epi proColon® 2.0 CE: a blood-based screening test for colorectal cancer. Mol Diagn Ther 2017 ; 21 : 225–232. [CrossRef] [Google Scholar]
  25. Rasmussen SL, Krarup HB, Sunesen KG, et al. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS One 2017 ; 12 : e0180809. [CrossRef] [PubMed] [Google Scholar]
  26. Rahier JF, Druez A, Faugeras L, et al. Circulating nucleosomes as new blood-based biomarkers for detection of colorectal cancer. Clin Epigenetics 2017 ; 9 : 53. [CrossRef] [Google Scholar]
  27. Jiang T, Zhai C, Su C, et al. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer 2016 ; 100 : 63–70. [CrossRef] [PubMed] [Google Scholar]
  28. Lin Z, Neiswender J, Fang B, et al. Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis. Oncotarget 2017 ; 8 : 26625–26636. [PubMed] [Google Scholar]
  29. Zhou Q, Li W, Leng B, et al. Circulating cell free DNA as the diagnostic marker for ovarian cancer: a systematic review and meta-analysis. PLoS One 2016 ; 11 : e0155495. [CrossRef] [PubMed] [Google Scholar]
  30. Hosgood HD, Liu CS, Rothman N, et al. Mitochondrial DNA copy number and lung cancer risk in a prospective cohort study. Carcinogenesis 2010 ; 31 : 847–849. [CrossRef] [PubMed] [Google Scholar]
  31. Thyagarajan B, Wang R, Barcelo H, et al. Mitochondrial copy number is associated with colorectal cancer risk. Cancer Epidemiol Prev Biomarkers 2012 ; 21 : 1574–1581. [CrossRef] [Google Scholar]
  32. Ashworth TR. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Australasian Med J 1869 ; 14 : 146–147. [Google Scholar]
  33. Tanaka F, Yoneda K, Kondo N, et al. Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res 2009 ; 15 : 6980–6986. [CrossRef] [PubMed] [Google Scholar]
  34. Fiorelli A, Accardo M, Carelli E, et al. Circulating tumor cells in diagnosing lung cancer: clinical and morphologic analysis. Ann Thorac Surg 2015 ; 99 : 1899–1905. [CrossRef] [Google Scholar]
  35. Ilie M, Hofman V, , Long-Mira E, et al. Sentinel circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease. PLoS One 2014 ; 9 : e111597. [CrossRef] [PubMed] [Google Scholar]
  36. Wang L, Wu C, Qiao L, et al. Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer. J Cancer 2017 ; 8 : 104–110. [CrossRef] [PubMed] [Google Scholar]
  37. Diaz LA, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014 ; 32 : 579–586. [CrossRef] [PubMed] [Google Scholar]
  38. Freidin MB, Freydina D V, Leung M, et al. Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies. Clin Chem 2015 ; 61 : 1299–1304. [CrossRef] [PubMed] [Google Scholar]
  39. Alix-Panabières C, , Pantel K. Characterization of single circulating tumor cells. FEBS Lett 2017 ; 591 : 2241–2250. [CrossRef] [PubMed] [Google Scholar]
  40. Roth C, Rack B, , Müller V, et al. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res 2010 ; 12 : R90. [CrossRef] [PubMed] [Google Scholar]
  41. Kodahl AR, Lyng MB, Binder H, et al. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol 2014 ; 8 : 874–883. [CrossRef] [PubMed] [Google Scholar]
  42. Tomasetti M, Amati M, Neuzil J, et al. Circulating epigenetic biomarkers in lung malignancies: from early diagnosis to therapy. Lung Cancer 2017 ; 107 : 65–72. [CrossRef] [PubMed] [Google Scholar]
  43. Adams DL, Adams DK, Alpaugh RK, et al. Circulating cancer-associated macrophage-like cells differentiate malignant breast cancer and benign breast conditions. Cancer Epidemiol Prev Biomarkers 2016 ; 25 : 1037–1042. [CrossRef] [Google Scholar]
  44. Gonzalez RM, Daly DS, Tan R, et al. Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased. Cancer Epidemiol Biomarkers Prev 2011 ; 20 : 1543–1551. [CrossRef] [Google Scholar]
  45. Sol N, Wurdinger T. Platelet RNA signatures for the detection of cancer. Cancer Metastasis Rev 2017 : 1–10. [Google Scholar]
  46. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med 2017; 9 : eaan2415. [CrossRef] [PubMed] [Google Scholar]
  47. Fernandez-Cuesta L, Perdomo S, Avogbe PH, et al. Identification of circulating tumor DNA for the early detection of small-cell lung cancer. EBioMedicine 2016 ; 10 : 117–123. [CrossRef] [PubMed] [Google Scholar]
  48. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018; eaar3247. [Google Scholar]
  49. Chan KCA, Woo JKS, King A, et al. Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. N Engl J Med 2017 ; 377 : 513–522. [CrossRef] [PubMed] [Google Scholar]
  50. Mouliere F, Robert B, Peyrotte EA, et al. High fragmentation characterizes tumour-derived circulating DNA. PLoS One 2011 ; 6 : e23418. [CrossRef] [PubMed] [Google Scholar]
  51. Leszinski G, Lehner J, Gezer U, et al. Increased DNA integrity in colorectal cancer. In Vivo (Brooklyn) 2014 ; 28 : 299–303. [PubMed] [Google Scholar]
  52. Thierry A, Messaoudi SE. Methods for screening a subject for cancer. WO2016/063122. [Google Scholar]
  53. Wang M, Ji S, Shao G, et al. Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients. Clin Transl Oncol 2017: 1–6. [PubMed] [Google Scholar]
  54. Loeb S, Catalona WJ. The prostate health index: a new test for the detection of prostate cancer. Ther Adv Urol 2014 ; 6 : 74–77. [CrossRef] [PubMed] [Google Scholar]
  55. Jordan B. Dépister les cancers asymptotiques ?. Med Sci (Paris) 2018 ; 34 : 363–365. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.